Atorvastatin in Pulmonary Hypertension

PHASE2CompletedINTERVENTIONAL
Enrollment

220

Participants

Timeline

Start Date

February 28, 2007

Primary Completion Date

March 31, 2010

Study Completion Date

May 31, 2010

Conditions
Hypertension, Pulmonary
Interventions
DRUG

Atorvastatin

Patients were assigned to receive 10 mg of atorvastatin for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.

DRUG

Placebo

Patients were assigned to receive 10 mg of placebo for 6 months (supplied by JiaLin Pharmaceutical Co., Beijing, China). The dose was adjusted to 5mg daily if serum transaminase levels increased by less than three times the upper limit of normal or creatine kinase levels increased to less than five times the upper limit of normal. If serum transaminase and creatine kinase levels remained normal and low-density lipoprotein level greater than 3.4mmol/L after 4 weeks of therapy, the dose of drug was increased to 20mg once daily.

Trial Locations (1)

100037

Cardiovascular Institute and Fu Wai Hospital, Beijing

All Listed Sponsors
collaborator

National Grant from The Ministry of Science and Technology

UNKNOWN

collaborator

Capital Development Scientific Fund

UNKNOWN

lead

Chinese Academy of Medical Sciences, Fuwai Hospital

OTHER

NCT00615823 - Atorvastatin in Pulmonary Hypertension | Biotech Hunter | Biotech Hunter